DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells

Creative Commons License

Sanlioglu A. D., KARACAY B., KOKSAL I. T., GRIFFITH T. S., Sanlioglu S.

CANCER GENE THERAPY, cilt.14, sa.12, ss.976-984, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 12
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1038/sj.cgt.7701087
  • Dergi Adı: CANCER GENE THERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.976-984
  • Anahtar Kelimeler: siRNA, DcR2, TRAIL, prostate, APOPTOSIS-INDUCING LIGAND, DEACETYLASE INHIBITORS MODULATE, CANCER-CELLS, MEDIATED APOPTOSIS, DOWN-REGULATION, UP-REGULATION, RESISTANCE, EXPRESSION, DEATH, SENSITIVITY
  • Akdeniz Üniversitesi Adresli: Evet

Özet

High levels of decoy receptor 2 (DcR2; TRAIL-R4) expression are correlated with TRAIL resistance in prostate cancer cells. In addition, upregulation of TRAIL death receptor (DR4 and DR5) expression, either by ionizing radiation or chemotherapy, can sensitize cancer cells to TRAIL. Considering more than half of human cancers are TRAIL resistant, modulation of surface TRAIL receptor expression appears to be an attractive treatment modality to counteract TRAIL resistance. In this study, three siRNA duplexes targeting DcR2 receptor were tested. Ad5hTRAIL infections were performed to overexpress human full-length TRAIL to induce cell death, and the in vitro tumorigenic potential of prostate cancer cells was assessed using colony-forming assays on soft agar. The DU145 and LNCaP prostate cancer cell lines, which express high levels of DcR2, were resistant to Ad5hTRAIL-induced death. Downregulation of surface DcR2 expression by siRNA sensitized these prostate cancer cell lines to Ad5hTRAIL. In addition, DcR2 siRNA-mediated knockdown of DcR2, followed by Ad5hTRAIL infection, dramatically reduced the in vitro tumorigenic potential of prostate cancer cells. Collectively, our results suggest the potential for combining receptor-specific siRNA with TRAIL in the treatment of certain cancers.